Ovid Therapeutics Inc.
OVIDAs of the close on Sep 25, 2026
Price
$2.40
Market cap
$469M
P/E (diluted TTM)
—
Per-share earnings are not available for each of the last four quarters
EPS (TTM)
—
Per-share earnings are not available for each of the last four quarters
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Ovid Therapeutics Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 11 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 17, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2026-03-31 | 152,847 | Not shown | SEC filing |
| Propel Bio Management, LLC | 2026-03-31 | 921,457 | Not shown | SEC filing |
| Velan Capital Investment Management LP | 2026-03-31 | 160,000 | Not shown | SEC filing |
| Total Clarity Wealth Management, Inc. | 2026-03-31 | 20,975 | Not shown | SEC filing |
| Quadrature Capital Ltd | 2026-03-31 | 111,804 | Not shown | SEC filing |
| TD Waterhouse Canada Inc. | 2026-03-31 | 30 | $65 | SEC filing |
| Abel Hall, LLC | 2026-03-31 | 31,189 | Not shown | SEC filing |
| BNP PARIBAS FINANCIAL MARKETS | 2026-03-31 | 992 | Not shown | SEC filing |
| Cetera Investment Advisers | 2026-03-31 | 17,000 | Not shown | SEC filing |
| Caitong International Asset Management Co., Ltd | 2026-03-31 | 4,384 | Not shown | SEC filing |
| Walleye Capital LLC | 2026-03-31 | 443,362 | Not shown | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 49,555 | Not shown | SEC filing |
| Point72 Asset Management, L.P. | 2026-03-31 | 1,320,610 | Not shown | SEC filing |
| UBS Group AG | 2026-03-31 | 277,656 | Not shown | SEC filing |
| AXQ CAPITAL, LP | 2026-03-31 | 85,411 | Not shown | SEC filing |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2026-03-31 | 6,163,781 | Not shown | SEC filing |
| Rosalind Advisors, Inc. | 2026-03-31 | 1,107,994 | Not shown | SEC filing |
| SBI Securities Co., Ltd. | 2026-03-31 | 107 | Not shown | SEC filing |
| GROUP ONE TRADING LLC | 2026-03-31 | 13,246 | Not shown | SEC filing |
| Bank of New York Mellon Corp | 2026-03-31 | 55,038 | Not shown | SEC filing |
- Each value is checked against Ovid Therapeutics Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 19 rows: the value per share could not be confirmed against the share prices on file from within three months of the report date.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Benin Management CORP: 19,000 shares reported 2025-12-31; 19,000 shares reported 2026-03-31.
- Saturn V Capital Management LP: 2,500,000 shares reported 2025-12-31; 4,166,666 shares reported 2026-03-31.
- Rockefeller Capital Management L.P.: 4,000 shares reported 2025-12-31; 4,000 shares reported 2026-03-31.
- RENAISSANCE TECHNOLOGIES LLC: 1,484,478 shares reported 2025-12-31; 1,104,300 shares reported 2026-03-31.
- BARCLAYS PLC: 1 share reported 2025-12-31; 1 share reported 2026-03-31.
- MARSHALL WACE, LLP: 1,271,487 shares reported 2025-12-31; 917,733 shares reported 2026-03-31.
- Clearstead Advisors, LLC: 2,734 shares reported 2025-12-31; 2,734 shares reported 2026-03-31.
- BlackRock, Inc.: 613,475 shares reported 2025-12-31; 1,533,283 shares reported 2026-03-31.
- FIRST MANHATTAN CO. LLC.: 26,000 shares reported 2025-12-31; 26,000 shares reported 2026-03-31.
- WELLS FARGO & COMPANY/MN: 720,848 shares reported 2025-12-31; 713,625 shares reported 2026-03-31.
- NISA INVESTMENT ADVISORS, LLC: 2,351 shares reported 2025-12-31; 2,351 shares reported 2026-03-31.
- Ally Bridge Group (NY) LLC: 1,785,000 shares reported 2025-12-31; 2,818,459 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
84 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Ovid Therapeutics Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2019-10-08 · MILLENNIUM PHARMACEUTICALS INC: Larger than all 9 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2019-10-08–2019-10-08: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2019-02-22–2019-02-26: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2018-08-14–2018-08-14: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-02-23 | Rona Jeffrey A · CBFO | Common Stock | S — Open market or private sale | −8,541 | 1.45 | SEC filing |
| 2026-02-23 | ALEXANDER MARGARET A. · President and CEO | Common Stock | S — Open market or private sale | −11,656 | 1.45 | SEC filing |
| 2025-12-11 | LEVIN JEREMY M · CEO | Series B Convertible Preferred Stock | P — Open market or private purchase | +71 | unknown | SEC filing |
| 2025-12-11 | LEVIN JEREMY M · CEO | Series A Warrant (right to buy) | P — Open market or private purchase | +47,333 | unknown | SEC filing |
| 2025-12-11 | LEVIN JEREMY M · CEO | Series B Warrant (right to buy) | P — Open market or private purchase | +35,500 | unknown | SEC filing |
| 2025-02-26 | ALEXANDER MARGARET A. · President and COO | Common Stock | S — Open market or private sale | −5,279 | 0.56 | SEC filing |
| 2025-02-26 | Rona Jeffrey A · CBFO | Common Stock | S — Open market or private sale | −3,902 | 0.56 | SEC filing |
| 2025-01-27 | ALEXANDER MARGARET A. · President and COO | Common Stock | P — Open market or private purchase | +6,810 | 0.73 | SEC filing |
Showing 8 of 16 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-15 | Greka Anna · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +130,000 | SEC filing |
| 2026-04-07 | Fitzgerald Kevin Joseph · Director | Common Stock | A — Grant, award, or other acquisition | +17,578 | SEC filing |
| 2026-04-07 | Friedman Bart · Director | Common Stock | A — Grant, award, or other acquisition | +8,789 | SEC filing |
| 2026-04-07 | PAPADOPOULOS STELIOS · Director | Common Stock | A — Grant, award, or other acquisition | +17,578 | SEC filing |
| 2026-03-23 | LEVIN JEREMY M · Executive Chairman | Common Stock | M — Exercise or conversion of derivative security | +47,333 | SEC filing |
| 2026-03-23 | LEVIN JEREMY M · Executive Chairman | Series A Warrant (right to buy) | M — Exercise or conversion of derivative security | −47,333 | SEC filing |
| 2026-02-26 | PAPADOPOULOS STELIOS · Director | Employee Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +65,000 | SEC filing |
| 2026-02-26 | ALEXANDER MARGARET A. · President and CEO | Employee Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +1,435,000 | SEC filing |
Showing 8 of 22 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2022-07-01 | TAKEDA PHARMACEUTICAL CO LTD · 10% owner | Series A Convertible Preferred Stock | J — Other acquisition or disposition | +1,250 | SEC filing |
| 2022-07-01 | TAKEDA PHARMACEUTICAL CO LTD · 10% owner | Common Stock | J — Other acquisition or disposition | −5,750,000 | SEC filing |
| 2022-07-01 | TAKEDA PHARMACEUTICAL CO LTD · 10% owner | Common Stock | J — Other acquisition or disposition | +5,750,000 | SEC filing |
| 2022-07-01 | TAKEDA PHARMACEUTICAL CO LTD · 10% owner | Series A Convertible Preferred Stock | J — Other acquisition or disposition | −1,250 | SEC filing |
Showing 4 of 4 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.